Abstract
Background
Cardiotoxicity resulting in heart failure (HF) is a devastating complication of cancer treatment. We profiled the characteristics of the patients who died within a cohort of blood and breast cancer patients who had an index heart failure admission after chaner diagnosis.
Methods
Linked Health Data for the period 1996-2009 from Queensland Cancer Registry (QCR), Death Registry and Hospital Administration records for HF and chemotherapy admissions were reviewed.
Results
During the time period of analysis there were 1,062 deaths in this cohort (51.4% Female), 882 (83.1%) blood and lymphatic cancer (41.8% Female), median age was 68 years (IQR 59-75) and 61.5 years (IQR 54-70), respectively. Blood cancer patients who had an index HF admission had increased risk of all-cause mortality (HR 1.74, 95% CI, 1.42-2.13] and 1.31 [95% CI, 1.04-1.65] after adjusting for age, sex, marital status, country of birth and number of chemotherapy doses and 1.67 times higher for the combined group. Index HF admission occurred within one year of cancer diagnosis in 51% and 27% of blood and breast cancer patients respectively (Total 78%), while 73.6% and 64% died (all-cause mortality) within one year of index HF admission.
Conclusion
All-cause mortality was higher in blood and lymphatic cancer patients than breast cancer in adjusted analysis for covariates. Heart Failure developed quickly after cancer treatment. Up to three quarters of the deaths occurred within one year of index HF admission.
Cardiotoxicity resulting in heart failure (HF) is a devastating complication of cancer treatment. We profiled the characteristics of the patients who died within a cohort of blood and breast cancer patients who had an index heart failure admission after chaner diagnosis.
Methods
Linked Health Data for the period 1996-2009 from Queensland Cancer Registry (QCR), Death Registry and Hospital Administration records for HF and chemotherapy admissions were reviewed.
Results
During the time period of analysis there were 1,062 deaths in this cohort (51.4% Female), 882 (83.1%) blood and lymphatic cancer (41.8% Female), median age was 68 years (IQR 59-75) and 61.5 years (IQR 54-70), respectively. Blood cancer patients who had an index HF admission had increased risk of all-cause mortality (HR 1.74, 95% CI, 1.42-2.13] and 1.31 [95% CI, 1.04-1.65] after adjusting for age, sex, marital status, country of birth and number of chemotherapy doses and 1.67 times higher for the combined group. Index HF admission occurred within one year of cancer diagnosis in 51% and 27% of blood and breast cancer patients respectively (Total 78%), while 73.6% and 64% died (all-cause mortality) within one year of index HF admission.
Conclusion
All-cause mortality was higher in blood and lymphatic cancer patients than breast cancer in adjusted analysis for covariates. Heart Failure developed quickly after cancer treatment. Up to three quarters of the deaths occurred within one year of index HF admission.
| Original language | English |
|---|---|
| Article number | 109 |
| Pages (from-to) | S55 |
| Number of pages | 1 |
| Journal | JOURNAL OF CARDIAC FAILURE |
| Volume | 21 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2015 |
| Event | 19th Annual Scientific Meeting Heart Failure Society of America - Duration: 26 Sept 2015 → … |
